Department of Medicine and.
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
JCI Insight. 2021 Jul 8;6(13):e149193. doi: 10.1172/jci.insight.149193.
BackgroundImmunomodulatory therapy may help prevent heart failure (HF). Data on immune cells and myocardial remodeling in older adults with cardiovascular risk factors are limited.MethodsIn the Multi-Ethnic Study of Atherosclerosis cohort, 869 adults had 19 peripheral immune cell subsets measured and underwent cardiac MRI during the baseline exam, of which 321 had assessment of left ventricular global circumferential strain (LV-GCS). We used linear regression with adjustment for demographics, cardiovascular risk factors, and cytomegalovirus serostatus to evaluate the cross-sectional association of immune cell subsets with left ventricular mass index (LVMI) and LV-GCS.ResultsThe average age of the cohort was 61.6 ± 10.0 years and 53% were women. Higher proportions of γ/δ T cells were associated with lower absolute (worse) LV-GCS (-0.105% [95% CI -0.164%, -0.046%] per 1 SD higher proportion of γ/δ T cells, P = 0.0006). This association remained significant after Bonferroni's correction. Higher proportions of classical monocytes were associated with worse absolute LV-GCS (-0.04% [95% CI -0.07%, 0.00%] per 1 SD higher proportion of classical monocytes, P = 0.04). This did not meet significance after Bonferroni's correction. There were no other significant associations with LV-GCS or LVMI.ConclusionPathways associated with γ/δ T cells may be potential targets for immunomodulatory therapy targeted at HF prevention in populations at risk.FundingContracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 and grant R01 HL98077 from the National Heart, Lung, and Blood Institute/NIH and grants KL2TR001424, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences/NIH.
背景
免疫调节疗法可能有助于预防心力衰竭（HF）。关于心血管危险因素的老年患者免疫细胞和心肌重构的数据有限。
方法
在动脉粥样硬化多民族研究队列中，869 名成年人接受了 19 种外周免疫细胞亚群的测量，并在基线检查期间进行了心脏 MRI 检查，其中 321 名成年人接受了左心室整体圆周应变（LV-GCS）评估。我们使用线性回归，调整了人口统计学、心血管危险因素和巨细胞病毒血清状态，以评估免疫细胞亚群与左心室质量指数（LVMI）和 LV-GCS 的横断面相关性。
结果
该队列的平均年龄为 61.6±10.0 岁，53%为女性。γ/δ T 细胞比例越高，绝对（更差）LV-GCS 越低（每 1 SDγ/δ T 细胞比例增加，LV-GCS 降低 0.105%[-0.164%，-0.046%]，P=0.0006）。在 Bonferroni 校正后，这种关联仍然显著。经典单核细胞比例越高，绝对 LV-GCS 越差（每 1 SD 经典单核细胞比例增加，LV-GCS 降低 0.04%[-0.07%，0.00%]，P=0.04）。在 Bonferroni 校正后，这并没有达到显著水平。与 LV-GCS 或 LVMI 无其他显著相关性。
结论
与 γ/δ T 细胞相关的途径可能是针对高危人群预防 HF 的免疫调节治疗的潜在靶点。
资金
合同 75N92020D00001、HHSN268201500003I、N01-HC-95159、75N92020D00005、N01-HC-95160、75N92020D00002、N01-HC-95161、75N92020D00003、N01-HC-95162、75N92020D00006、N01-HC-95163、75N92020D00004、N01-HC-95164、75N92020D00007、N01-HC-95165、N01-HC-95166、N01-HC-95167、N01-HC-95168 和 NIH 国家心脏、肺和血液研究所的 R01 HL98077 拨款以及国家转化医学中心的 KL2TR001424、UL1-TR-000040、UL1-TR-001079 和 UL1-TR-001420 拨款。
Zotero 插件